Oruka Therapeutics Promotes Laura Sandler to Chief Operating Officer
Oruka Therapeutics Inc., a clinical-stage biotech company listed on Nasdaq under the ticker ORKA, has announced the promotion of Laura Sandler to the position of Chief Operating Officer. This strategic move comes as the company continues to advance its pipeline of novel biologics aimed at treating chronic skin diseases.
Laura Sandler, who joined Oruka in 2024 as Senior Vice President of Operations, brings a wealth of experience to her new role. With over 20 years in the biopharmaceutical industry, Sandler has held senior positions at several leading companies, including CRISPR Therapeutics, MedImmune, Quintiles, Novartis, and bluebird bio. At CRISPR Therapeutics, she was instrumental in the development of exa-cel, the first approved CRISPR-based medicine, showcasing her expertise in bringing innovative therapies to market.
The promotion of Sandler to COO is expected to bolster Oruka’s operational capabilities as it navigates the complex landscape of biopharmaceutical development. Her extensive background in development operations and leadership positions aligns with Oruka’s mission to develop genetically targeted therapies for chronic skin conditions.
As of June 29, 2025, Oruka’s stock closed at $11.21, with a market capitalization of approximately $435.43 million. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of $52.32 on August 22, 2024, and a low of $5.49 on April 8, 2025.
This leadership change is part of Oruka’s ongoing efforts to strengthen its executive team and enhance its strategic initiatives in the biotechnology sector. The company remains focused on its core mission of developing innovative treatments for cardiovascular diseases and chronic skin conditions, leveraging its expertise in genetically targeted therapies.
For more information on Oruka Therapeutics and its developments, stakeholders can refer to the company’s official announcements and financial reports.